(Reuters) - An experimental melanoma drug from GlaxoSmithKline managed to shrink secondary tumors in the brains of nine patients with advanced disease, according to results of a small clinical trial on Sunday.
(Reuters) - An experimental melanoma drug from GlaxoSmithKline managed to shrink secondary tumors in the brains of nine patients with advanced disease, according to results of a small clinical trial on Sunday.